Welcome to Multibagg AI
Log in to access personalized features
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q1 FY22
Investor Presentation
Q2 FY20
Investor Presentation
Q1 FY20
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY19
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Conference & Pipeline
Suven Life Sciences will present its differentiated CNS clinical portfolio and partnering strategy at BIO‑2026 in San Diego, highlighting positive Phase‑2b Ropanicant results and progress in multiple Phase‑3 programs.
Public Notice/Press Release
Suven Life Sciences Ltd will participate in BIO International Convention 2026 (June 22-25) in San Diego to showcase its differentiated CNS clinical candidates, seek partnering/out-licensing via 62 pre-scheduled meetings and highlight positive Phase-2b results for Ropanicant.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Suven Life Sciences Ltd (SUVEN) is currently trading at 254.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company primarily focused on developing novel therapeutics for neurodegenerative disorders. Its operations include Contract Research And Manufacturing Services (CRAMS), offering process research, clinical trial supplies, and exclusive manufacturing services. The company has expanded its drug discovery into areas such as Major Depressive Disorder, pain management, and obesity, showcasing its specialization in CNS-based programmes. Suven's subsidiary, Suven Neurosciences, Inc., USA, is dedicated to advancing clinical studies of Suven molecules, indicating significant investments in international operations related to CNS therapies. In FY15, Suven entered into an exclusive licensing agreement with Taro Pharmaceuticals for its Malathion lotion, expected to yield revenue and royalties from the US, Canada, and Mexico markets. Several new molecules have been added to Suven's drug pipeline, with significant investments in R&D and clinical trials, reinforcing their commitment to addressing niche medical needs.
Over the past 52 weeks, Suven Life Sciences Ltd has traded between a low of ₹124.35 and a high of ₹303.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Suven Life Sciences Ltd has a market capitalization of approximately 6,829.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Suven Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -24.71 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,829.49 Cr, Suven Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Suven Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Suven Life Sciences Ltd is -24.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
After reviewing unblinded safety data from about half the participants who completed 12 weeks of treatment, the DSMB found no safety concerns and recommended the trial continue without modifications.
Management expects key readouts in 2027, led by Phase 3 data for SUVN-502 (Masupirdine), with other pipeline molecules also discussed as approaching major results around the same period.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
526.50 | 12,768 Cr | 31.83 | 4.07 | 0.42 | 12.78 | 15.61 | 8.68 | ||
255.90 | 6,829 Cr | -24.71 | 11.55 | 0.00 | -46.73 | -45.42 | -44.27 | ||
585.20 | 2,138 Cr | 34.83 | 6.24 | 0.21 | 14.59 | 19.04 | 13.94 | ||
29.33 | 443 Cr | 40.81 | 14.28 | 0.00 | 13.73 | 15.37 | 29.94 | ||
81.75 | 163 Cr | -1021.00 | 2.27 | 0.00 | 1.60 | 4.43 | 0.97 | ||
57.00 | 136 Cr | -74.91 | 0.69 | 0.00 | 2.81 | 6.68 | -3.69 | ||
26.81 | 97 Cr | 33.86 | 1.69 | 0.00 | 5.01 | 4.64 | 4.27 | ||
| Median: 7 Co. | — | 81.75 | 443 Cr | 31.83 | 4.07 | 0.00 | 5.01 | 6.68 | 4.27 |
Bearish
4
Neutral
7
Bullish
3
Bearish
21
Neutral
7
Bullish
18
Bearish
17
Neutral
0
Bullish
15
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company primarily focused on developing novel therapeutics for neurodegenerative disorders. Its operations include Contract Research And Manufacturing Services (CRAMS), offering process research, clinical trial supplies, and exclusive manufacturing services.
The company has expanded its drug discovery into areas such as Major Depressive Disorder, pain management, and obesity, showcasing its specialization in CNS-based programmes.
Suven's subsidiary, Suven Neurosciences, Inc., USA, is dedicated to advancing clinical studies of Suven molecules, indicating significant investments in international operations related to CNS therapies.
In FY15, Suven entered into an exclusive licensing agreement with Taro Pharmaceuticals for its Malathion lotion, expected to yield revenue and royalties from the US, Canada, and Mexico markets.
Several new molecules have been added to Suven's drug pipeline, with significant investments in R&D and clinical trials, reinforcing their commitment to addressing niche medical needs.
Healthcare Services
Healthcare Research, Analytics & Technology
6,705 Cr
High Risk
-24.3
59.9
—
11.6
303.00
124.35
Sales CAGR
Profit CAGR
ROE
ROCE
